Karim Meghji is a well-seasoned scientist with 25 years work experience in pharmaceutical, biopharmaceutical, CRO/CMO and CDMO companies. He acquired his MSc. in Biology from the University of Waterloo where he conducted research in microbial biotechnology and wrote a thesis on production, purification, and characterization of extracellular carboxylesterases from B. subtilis.
As a graduate teaching assistant, he was awarded an honorable mention for excellence in teaching by the University of Waterloo. Prior to joining NACPT, Karim worked as a senior scientist in a CDMO and generics company called DPT Labs, in San Antonio, Texas (now acquired by Mylan N.V.), that specialized in topical dermatologic products. Karim has also worked for companies like QLT Inc. in Vancouver that developed the blockbuster photodynamic therapy drug Visudyne for wet age-related macular degeneration and worked as a research associate and safety officer for a leading CRO/CMO company formerly called Northern Lipids, Inc (now Evonik Transferra Nanosciences) in Vancouver, specializing in development and manufacture of complex drug delivery systems using lipid nanoparticle science. In these companies, Karim was responsible for optimizing, developing and validating HPLC and GC methods for analysis of peptides, cytotoxics, small molecules, siRNA and dsRNA in liquid, semi-solid, aerosol foam and liposomal drug formulations. In his role as CMC Manager in a virtual biotechnology company formerly called Protox Therapeutics Inc (acquired by Sophiris Bio Inc) in Vancouver, Karim oversaw and managed all chemistry, manufacturing and control aspects of the company’s pipeline by successfully working with third-party contractors. Karim has working knowledge of cGMP, GLP, FDA (CDER and CBER), Health Canada, USP and ICH compliance, has excellent oral and written communication skills with strong interpersonal skills and is fluent in five languages.